The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / International Task Force Recommends Intra-articular Hyaluronic Acid for Knee OA

International Task Force Recommends Intra-articular Hyaluronic Acid for Knee OA

June 15, 2017 • By Kathy Holliman

  • Tweet
  • Email
Print-Friendly Version / Save PDF
ESCEO recommends systematic repeated intra-articular hyaluronic acid injections as second-line treatment for patients with knee OA.

ESCEO recommends systematic repeated intra-articular hyaluronic acid injections as second-line treatment for patients with knee OA.
cunaplus/shutterstock.com

An international task force convened by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) recommends systematic repeated intra-articular hyaluronic acid (HA) injections as second-line treatment for patients with knee osteoarthritis (OA). This is the first time a group of experts has made this recommendation, which is directed toward treatment of patients who have had a beneficial response with a previous cycle of treatment.1

You Might Also Like
  • OA Patient-Reported Outcomes Positive for Intra-Articular Injection
  • 2015 ACR/ARHP Annual Meeting: Novel Approaches for Intra-Articular Arthritis Therapy
  • Clinical Remission Should Be Target of JIA Treatment: Task Force
Explore This Issue
June 2017
Also By This Author
  • ACR 2013 State-of-the-Art Clinical Symposium: The Challenge of Treating Low Back Pain

The review article highlights the safety profile of the treatment and its “moderate but real” efficacy on symptoms. The efficacy of intra-articular HA, according to the review, is in the same range as other pharmacologic modalities used for knee OA, but does not have the vascular and gastrointestinal toxicity of acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs) or the adverse events associated with corticosteroid injections in some patients.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The ESCEO task force recommends that intra-articular HA be used in patients who remain symptomatic despite continuous or intermittent treatment with conventional pharmacologic treatment modalities, such as acetaminophen, symptomatic slow-acting drugs and NSAIDs, and in patients with comorbidities that preclude the use of NSAIDs. The evidence for this recommendation was drawn from real-life clinical data.

“The medical community cannot afford to neglect the use of [intra-articular] HA, particularly now that systematic repetitive treatment cycles have been shown to yield positive results in terms of both efficacy and safety,” the task force members said. The review “encourages the use of repeated cycles of [intra-articular] HA in patients who responded to the first injection, starting a new treatment cycle as soon as the first symptoms appear.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Additionally, the task force found no current clinical evidence supporting an advantage in efficacy of one intra-articular HA product over another. If intrinsic properties of a product, such as its molecular weight, provide a beneficial result when compared with other intra-articular HA products, “characteristics related to the patient are likely to prevail,” the authors said.

Professional Guidelines

The task force notes that other professional groups have weighed in on the efficacy of intra-articular HA for treatment of knee OA. “However, while IAHA was initially clearly recommended by national and international professional societies, such as the Osteoarthritis Research Society International (OARSI), the European League Against Rheumatism (EULAR) and the [ACR], some clinicians, researchers and decision makers feel that current guidelines are conflicting and less favorable than 10 years ago,” the review states.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Osteoarthritis Tagged With: Clinical, European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, guideline, hyaluronic acid, joint, knee, OA, Osteoarthritis, outcome, patient care, recommendation, rheumatologist, rheumatology, TreatmentIssue: June 2017

You Might Also Like:
  • OA Patient-Reported Outcomes Positive for Intra-Articular Injection
  • 2015 ACR/ARHP Annual Meeting: Novel Approaches for Intra-Articular Arthritis Therapy
  • Clinical Remission Should Be Target of JIA Treatment: Task Force
  • The ACR Extends Its Global Outreach with a New Task Force

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.